Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease

Journal of Digestive Diseases

Volumn 13, Issue 11, 2012, Pages 588-595

  Xun, Yun Hao ^a,b   Fan, Jian Gao ^c   Zang, Guo Qing ^a   Liu, Hong ^b   Jiang, Yan Ming ^b   Xiang, Jing ^b   Huang, Qian ^b   Shi, Jun Ping ^b,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Biopsy; China; Diagnosis; Fibrosis; Non alcoholic fatty liver disease

Indexed keywords

ADULT; ADVANCED FIBROSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE ALANINE TRANSAMINASE RATIO; ASPARTATE TRANSAMINASE PLATELET RATIO INDEX; BODY MASS INDEX AAR DIABETES; CHINESE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FEMALE; FIB-4 INDEX; FIBROSIS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NAFLD FIBROSIS SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; BIOPSY; BODY MASS INDEX; CHINA; COHORT STUDIES; DIABETES MELLITUS; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET COUNT; PREVALENCE; REPRODUCIBILITY OF RESULTS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84868119124     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2012.00631.x     Document Type: Article

References (32)

1. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044.
3. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335.
4. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269.
5. Raszeja-Wyszomirska J, Szymanik B, Ławniczak M etal. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010; 10: 67.
6. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112.
7. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
8. Ruffillo G, Fassio E, Alvarez E etal. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 160-163.
9. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.
10. Wong VW, Wong GL, Chim AM etal. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103: 1682-1688.
11. Angulo P, Hui JM, Marchesini G etal. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
12. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462.
13. Fan JG, Jia JD, Li YM etal; Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis 2011; 12: 38-44.
14. IASO International Association for the Study of Obesity. The Asia Pacific perspective: Redefining obesity and its treatment (2000). Cited: 23 May 2011. Available from URL: http://www.wpro.who.int/nutrition/documents/Redefining_obesity/en/index.html.
15. Sterling RK, Lissen E, Clumeck N etal; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
16. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
17. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-739.
18. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447.
19. Kleiner DE, Brunt EM, Van Natta M etal; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
20. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004; 8: 508-512.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
22. Calès P, Lainé F, Boursier J etal. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-173.
23. Neuschwander-Tetri BA, Clark JM, Bass NM etal; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-924.
24. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: 1566-1567; author reply 1567.
25. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540.
26. Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26: 802-809.
27. Castéra L, Foucher J, Bernard PH etal. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-835.
28. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC; Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-1370.
29. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 Suppl 1: 63-69.
30. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36-41.
31. Poynard T, Halfon P, Castera L etal; FibroPaca Group. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007; 25: 733-739.
32. Wong VW, Chan HL. Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test? J Gastroenterol Hepatol 2011; 26: 419-420.